The dense glycocalyx surrounding the protozoan parasite Leishmania is an essential virulence factor. It protects the parasite from hostile environments in the sandfly vector and mammalian host and supports steps of development and invasion. Therefore, new therapeutic concepts concentrate on disturbing glycocalyx biosynthesis. Deletion of genes involved in the metabolism of galactose and mannose have been shown to drastically reduce Leishmania virulence. Here we report the identification of Leishmania major UDP-glucose pyrophosphorylase (UGP). UGP catalyzes the formation of UDP-glucose from glucose 1-phosphate and UTP. This activation step enables glucose to enter metabolic pathways and is crucial for the activation of galactose. UDP-galactose is made from UDP-glucose by nucleotide-donor transfer to galactose 1-phosphate or by epimerization of the glucose moiety. Isolated in a complementation cloning approach, the activity of L. major UGP was proven in vitro. Moreover, purified protein was used to investigate enzyme kinetics, quaternary organization, and binding of ligands. Whereas sequestration by oligomerization is a known regulatory mechanism for eukaryotic UGPs, the recombinant as well as native L. major UGP migrated as monomer in size exclusion chromatography and in accord with this showed simple Michaelis-Menten kinetics toward all substrates. In saturation transfer difference (STD)-NMR studies, we clearly demonstrated that the molecular geometry at position 4 of glucose is responsible for substrate specificity. Furthermore, the â„-phosphate group of UTP is essential for binding and for induction of the open conformation, which then allows entry of glucose 1-phosphate. Our data provide the first direct proof for the ordered bi-bi mechanism suggested in earlier studies.Leishmania are protozoan parasites that cause severe diseases in human and animals. Depending on the Leishmania strain, disease manifestations can range from self-healing cutaneous lesions to fatal visceral forms (1). Based on records of the World Health Organization, 12 million people are infected worldwide, but no vaccine or specific drug is available to prevent or treat Leishmaniasis.Leishmania are covered by a dense glycoconjugate layer, the glycocalyx, which helps the parasite to withstand hostile environments in the sandfly vector and mammalian host. Moreover, structural changes in glycocalyx components accompany the life cycle of the parasites and are crucial for the transmission of the parasite (2, 3).A major component of the glycoconjugates is galactose, which is dynamically added in the Golgi apparatus. Both transport of galactose to the Golgi lumen and insertion into glycoconjugates depend on the synthesis of the nucleotide sugar UDP-Gal in the cytoplasm of the cell. Whereas synthesis of most nucleotide sugars is catalyzed by pyrophosphorylases using the respective nucleotide triphosphate as substrate (for a review, see Ref. 4), activation of galactose is achieved by nucleotide exchange between UDP-Glc and galactose 1-phosphate (Gal-...